Remission induction in a phase 1 study of a bispecific single chain immunotoxin targeting CD22 and CD19 (DT2219) for refractory B-Cell malignancies

Category Primary study
JournalBlood
Year 2014
This article has no abstract
Epistemonikos ID: 69ee85f03cfa7a7b66d04197fe59adb45cc4aa99
First added on: Feb 06, 2025